1409936-68-0

Basic information

• Product Name: L-proline-(2S,3R,4R,5S,6R)-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
• Synonyms: L-proline-(2S,3R,4R,5S,6R)-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
• CAS NO: 1409936-68-0
• Molecular Weight: 559.656
• Mol File: 1409936-68-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: L-proline-(2S,3R,4R,5S,6R)-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol(CAS DataBase Reference)
• NIST Chemistry Reference: L-proline-(2S,3R,4R,5S,6R)-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol(1409936-68-0)
• EPA Substance Registry System: L-proline-(2S,3R,4R,5S,6R)-2-{3-[5-(4-fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol(1409936-68-0)

Safety Data

• Hazardous Substances Data: 1409936-68-0(Hazardous Substances Data)

Upstream product

• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 
• 1335-57-5 3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-one 
• 842133-18-0 canagliflozin 
• 147-85-3 L-proline 

Relevant articles and documents

A NOVEL PROCESS FOR PREPARING (2S,3R,4R,5S,6R)-2-{3-[5-[4-FLUORO-PHENYL)- THIOPHEN-2-YLMETHYL]-4-METHYL-PHENYL}-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,4,5- TRIOL AND ITS STABLE AMORPHOUS HEMIHYDRATE FORM

The present invention discloses the process for preparation of (2S,3R,4R,5S,6R)-2-{3-[5- [4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol and its stable amorphous hemihydrate form.

L-PROLINE AND CITRIC ACID CO-CRYSTALS OF (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL

The present invention is directed to L-proline and citric acid co-crystals of (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, pharmaceutical compositions containing said co-crystals and their use in the treatment glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.